Quectel Releases New 4G/5G, LPWA and GNSS Antennas to Help Customers Optimize Device Performance
11.7.2023 12:00:00 EEST | Business Wire | Press release
Quectel Wireless Solutions, an IoT global solutions provider, proudly announces the launch of an exciting line-up of antennas designed to meet a wide spectrum of requirements:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230711943901/en/
Quectel releases new 4G/5G, LPWA and GNSS antennas to help customers optimize device performance (Photo: Business Wire)
- YEMN926J1A: This state-of-the-art 9-in-1 5G screw mount combo antenna is at the forefront of technology. It offers superior performance for 5G networks and is designed with a screw mount for easy installation.
- YECW000N1A: This external antenna is specifically optimized for low power wide area (LPWA) networks. It provides excellent connectivity for LPWA applications and ensures reliable and efficient communication.
- YEGT000W8A: Our advanced active global satellite navigation system (GNSS) L1 and L5 antenna, ideal for precise positioning and timing. It offers enhanced accuracy and reliability for GNSS applications.
These antennas showcase cutting-edge technology and are designed to meet the demands of today's connectivity requirements.
“We’re proud to launch these three new antennas which further add to our range of 4G/5G, LPWA and GNSS antennas,” said Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “Antennas are often overlooked during device development but it’s important to enable developers with antennas that can be optimized for their specific use cases and provide them with the performance they need to meet their application needs. These new antennas provide customers with even greater opportunities to optimize their solutions as they build a smarter world.”
The YEMN926J1A is a 9-in-1 5G screw mount combo antenna optimized for 5G and 4G networks. It includes a GNSS antenna and measures 167mm x 57mm. Both RoHS and REACH compliant, the combo antenna also is IP67 and IP69K rated which means it offers complete protection against ingress of dust and airborne particles as well as protection against water and liquids up to and including immersion in up to 1m of water. The IP69K rating also means the product can withstand washdown pressure of 80-100 bar in phases of 14-16 l/min at temperatures of up to 80°C.
The ultra-wide-band 5G/4G antenna box provides broad coverage from 600-6,000MHz while offering support for 3G and 2G networks as well at Cat-M and NB-IoT. The antenna is designed to work with various ground plane sizes or in free space for ease of integration with nine cable connections on the antenna as required and cable length options from 300mm to 5000mm, terminated with SMA connectors. The screw mount omnidirectional antenna is easy to install with maximized durability and is compatible with Quectel's RM520x series modules.
The YECW000N1A external antenna offers high efficiency with a low profile and is optimized for LPWA connections. With dimensions of 149.73mm x 49.91mm x 35.5mm, the antenna operates in the 450-470MHz, 700-960MHz and 1710-2690MHz frequency bands. The external 4G antenna covers the main LTE bands and is also compatible with 3G, 2G and LPWA bands.
RoHS compliant, the YECW000N1A has been carefully designed so it is minimally influenced by the internal environment of devices it is connected to. This enables it to deliver better efficiency, radiation and gain while providing optimized performance for customers’ products. A further advantage is that Quectel offers flexible installation options with custom cable lengths and connectors available.
Completing Quectel’s latest antenna introductions, the YEGT000W8A is an active GNSS L1 and L5 antenna that supports the 1164-1189MHz and 1559-1606MHz frequency bands. With dimensions of 65mm x 45mm, the GNSS antenna is RoHS and IP67 compliant.
The YEGT000W8A offers a choice of configurations to guarantee the most suitable polarization type and was specifically developed for 5G RAN timing. Quectel’s positioning products support single-band or multi-band operation modes to meet various high- precision positioning requirements of customers’ products. Customized connector types and cable lengths are provided according to customers’ requirements.
In addition to providing antennas, Quectel also provides comprehensive antenna design support which includes simulation, testing and manufacturing for custom antenna solutions to meet customers’ specific application needs. This support, allied to innovative antennas, helps enable customers to optimize device performance.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules, antennas, services and IoT connectivity.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.quectel.com, LinkedIn, Facebook, and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230711943901/en/
Contact information
Media: media@quectel.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom